Results 151 to 160 of about 313,244 (194)
Some of the next articles are maybe not open access.

Recombinant immunotoxins for the treatment of haematological malignancies

Expert Opinion on Biological Therapy, 2004
Recombinant immunotoxins are fusion proteins which contain a ligand derived from the immune system fused to a toxin. The protein toxin is truncated to delete its binding domain, allowing selective ligand-directed binding. Growth factor fusion toxins are often considered immunotoxins. One of these molecules, containing the truncated diphtheria toxin and
openaire   +2 more sources

Generation of Single-Domain Antibody-Based Recombinant Immunotoxins

2022
The discovery of single-domain antibodies has opened new avenues for drug development. Single-domain antibodies, also known as nanobodies, can access buried epitopes that are inaccessible to conventional antibodies. These antigen-binding domains have a high level of solubility and stability, which makes them well suited for therapeutic development ...
Bryan D. Fleming, Mitchell Ho
openaire   +2 more sources

Pseudomonas Exotoxin and Recombinant Immunotoxins Derived from It

Annals of the New York Academy of Sciences, 1993
Pseudomonas exotoxin (PE) is a bacterial toxin that kills mammalian cells by gaining entry to the cytosol and inactivating protein synthesis. The toxin binds and enters cells via the alpha 2-macroglobulin receptors. Within cells, the toxin is processed in several steps to produce an enzymatically active 37-kDa C-terminal fragment which translocates to ...
D, Fitzgerald, I, Pastan
openaire   +2 more sources

Recombinant immunotoxins: protein engineering for cancer therapy

Molecular Medicine Today, 1996
Recombinant immunotoxins for cancer therapy are composed of the variable regions of 'cancer-specific' antibodies fused to truncated toxins that are usually derived from bacteria or plants. Protein engineering has been used to modify these molecules so that the toxin moiety by itself does not bind to normal human cells, but retains all other cytotoxic ...
openaire   +2 more sources

Anti-CD30 immunotoxins with native and recombinant dianthin 30

Cancer Immunology, Immunotherapy, 1995
Immunotoxins were prepared with a Ber-H2 (anti-CD30) monoclonal antibody and native or recombinant dianthin 30, a ribosome-inactivating protein from Dianthus caryophyllus (carnation). Both immunotoxins selectively inhibited protein synthesis by CD30+ cell lines D430B (lymphoblastoid, infected with Epstein-Barr virus), L428 and L540 (both from Hodgkin's
Bolognesi A   +6 more
openaire   +3 more sources

A recombinant, membrane-acting immunotoxin.

Cancer research, 1991
The anti-Tac antibody is known to bind to the p55 chain of the human interleukin 2 receptor. An immunotoxin was produced by genetically linking Clostridium perfringens phospholipase C (PLC) to the Fab domain of anti-Tac. For this purpose, the PLC gene, with its own promoter and signal sequence, was fused to the 5' end of the VHCH1 segment of the anti ...
A, Chovnick   +4 more
openaire   +1 more source

Recombinant Immunotoxins for Chronic Inflammatory Disease

2017
Over the last couple of decades, a demographic transition towards an aging population has occurred. This has been accompanied by an increase in chronic inflammatory disorders like atopic dermatitis, rheumatoid arthritis, and diabetic ulcers, as many of these are strongly age related.
Theo Thepen, Stefan Barth
openaire   +1 more source

Recombinant immunotoxins in targeted cancer cell therapy

2001
Targeted cancer therapy in general and immunotherapy in particular combines rational drug design with the progress in understanding cancer biology. This approach takes advantage of our recent knowledge of the mechanisms by which normal cells are transformed into cancer cells, thus using the special properties of cancer cells to device novel therapeutic
openaire   +2 more sources

Recombinant Immunotoxins with Low Endotoxins for Clinical and Animal Studies

2012
Recombinant immunotoxin (RIT) contains the Fv portion of the antibody fused to the truncated form of toxin and are ongoing in clinical trials for cancer therapy. To obtain high yields of products, RITs are produced in Escherichia coli (E. coli). As the endotoxin came from E. coli cells and is harmful to animals, it is important to produce the RITs with
openaire   +2 more sources

Home - About - Disclaimer - Privacy